| CDKN2A |
| LOCUS ID | 1029 | |||||||||||||
| GENE_SYMBOL | CDKN2A | |||||||||||||
| GENE NAME | cyclin-dependent kin | |||||||||||||
| SYNONYMNS | ARF, MLM, P14, P16, P19, | |||||||||||||
| CHROMOSOME | 9 | |||||||||||||
| HOMOLOGENE ID | 55430 |
| microRNAs | NA | NA |
| GENE SUMMARY |
|---|
| This gene generates several transcript variants which differ in their first exons. At least three altertively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alterte first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alterte open reading frame (ARF) that specifies a protein which is structurally unrelated t |
| OBSERVATIONS |
|---|
| Complication | Evidence | PMID |
| Cardiovascular | 1. WFS1, CDKN2A/B, CDC123/CAMK1D, JAZF1, FTO, CDKAL1, and HHEX/IDE are associated with cardiovascular risk. | 23298195 |
| Atherosclerosis | Thus, atherosclerosis complications in T2DM associate with altered immune cell homeostasis, diminished CDKN2A/2B/2BAS expression, and increased CDK4 levels. The present study also suggests that the treatment with drugs that mimic CDKN2A/2B genes could potential be considered as a promising therapy to delay atherosclerosis. | 30176239 |